Cardiac troponin I (cTnI) and cTnT measurements are used in the diagnosis of acute myocardial infarction (AMI). Together with troponin C (TnC), the cTnI and cTnT forms make up the ternary cTnT-cTnITnC (TIC) complex found within myocardium. Whether cTn occurs in the circulation after AMI as ternary TIC, binary cTnI-TnC (IC) complexes, or free troponin forms has not been thoroughly investigated.
The troponin complex, a component of thin filaments of skeletal and cardiac muscles, comprises troponin C (TnC) 4 (18 kDa), troponin T (TnT) (37 kDa), and troponin I (TnI) (21-24 kDa). Detection of an increase in the serum concentration of cardiac troponin I (cTnI) or T (cTnT), combined with evidence of myocardial ischemia, is used in the diagnosis of acute myocardial infarction (AMI) (1 ) . Although measurement of cTn is the standard biochemical test for diagnosis of AMI, little is known about the forms of troponin released into the circulation after an AMI or which forms react in cTn assays currently in clinical use. Studies of these issues have used a variety of analytical techniques, which have contributed complementary, but sometimes conflicting, information. Specific immunoassays have shown that the majority of cTnI circulating after AMI is present as a binary cTnI-TnC (IC) complex (2, 3 ) with little free cTnI. The presence of the ternary cTnT-cTnI-TnC (TIC) complex was identified as a minor component on occasion. Further information on the nature of the circulating cTnI species has been obtained by studies using SDS-PAGE and Western blotting. Using this technique, Morjana (4 ) found that the majority of cTnI detected in AMI patient sera was truncated at the N-and C-terminals as a result of proteolytic processing. Labugger et al. (5, 6 ) , using SDS-PAGE with Western blotting, confirmed that N-and C-terminal truncated forms of cTnI were present in serum after AMI. In contrast to Morjana (4 ) , Labugger et al. found that intact cTnI was the predominant form. Because these modified forms were not produced after incubation of recombinant cTnI with pooled serum, it was suggested that they were produced in the ischemic myocardium and might be of pathological significance (5 ) . Further evidence for this interpretation was obtained by Katrukha et al. (7 ) , who demonstrated proteolytic degradation of cTnI by human necrotic myo-cardium in vitro and also the ability of truncated forms of free cTnI to bind to TnC. These authors (7 ) suggested that clinical assays for cTnI should use antibodies that recognize epitopes in the central portion of the cTnI molecule, which was least susceptible to proteolysis, so that assays would detect all forms of cTnI present in the circulation.
SDS-PAGE with Western blotting performed by using a research anti-cTnT antibody was also applied to the study of cTnT. It was shown that intact cTnT rapidly disappeared from the circulation after AMI, but a number of truncated forms remained for longer time periods (5, 8 ) . As with SDS-PAGE, gel filtration chromatography (GFC) separates species on the basis of molecular mass. GFC lacks the resolution and sensitivity of SDS-PAGE but has the advantages of having quantifiable recovery, involving minimal sample manipulation and allowing the direct application of current clinical assays to the detection of cTn in the GFC fractions. GFC may provide information different from that obtained with other techniques, but it has not been widely used to study the forms of troponin circulating after AMI. Wu et al. (9 ) , who used GFC with clinical assays for cTnI and cTnT, confirmed in 3 patients, that cTnI was present predominantly as a binary IC complex. In 2 patients the TIC complex was observed as a minor component, and no free cTnI was detected. However, in contrast to the findings with SDS-PAGE (4 -6 ), intact free cTnT appeared to be the predominant form of cTnT present, and there was some evidence of free, low molecular mass cTnI and cTnT. Discrepancies between the results of SDS-PAGE and GFC have also been found in studies of the circulating form of cTnT in patients with kidney failure (10 -12 ) , and results of our preliminary studies indicated similar findings in patients after AMI (10 ) . Currently only 1 study has addressed whether there are temporal changes in cTn forms after AMI (8 ) but this study used antibodies not in clinical use.
In the present study we set out to determine the circulating forms of cTn in patients with ST-elevation myocardial infarction by using GFC and measurement of cTnT and cTnI with assays currently in clinical use. The pattern of release of the different cTn forms was examined in relation to time after onset of chest pain. The use of 2 different cTnI assays enabled us to investigate whether any observed patterns of cTnI release were related to differing reactivities of cTnI immunoassays.
Materials and Methods
We recruited 13 patients who were treated at the emergency care center of the Kent and Canterbury Hospital ( Blood samples were collected at time of presentation (or after initiation of thrombolysis in those patients who underwent thrombolysis) and then approximately 12, 24, and 48 h after the onset of chest pain. The median time after onset of chest pain that the initial samples were collected was 3 h (range 1-10 h). Blood was collected into Becton Dickinson vacutainers (plain, red top 3 ϫ 7 mL) and allowed to clot before centrifugation and separation of the serum. Creatinine and total cTnT were measured in each serum sample immediately after collection, and the serum was then stored at Ϫ80°C before measurement of total cTnI and further analysis by use of GFC.
We performed GFC as previously described (10 ) on Sephacryl S-100 gel (Amersham Biosciences; molecular mass separation range 1-100 kDa) using a 40 ϫ 1.6 -cm column (bed volume 75 mL). The column was calibrated with ovalbumin (43 kDa), chymotrypsinogen A (25 kDa), and ribonuclease A (14 kDa) (Amersham Biosciences). To compensate for the influence of relatively large sample volumes on the variability of elution volume, we used endogenous serum albumin and prolactin as internal markers of molecular mass as previously described (10 ) . Depending on the cTnT concentration in the sample, 0.5-2.0 mL serum was applied to the top of the column and eluted with Tris buffer (pH 7.4) containing 0.26 mol/L NaCl, 2.49 mmol/L CaCl 2 -2H 2 O, 0.02 mol/L Tris, 6 mmol/L NaN 3 , and 1 g/L bovine serum albumin. Fractions of approximately 1.25 mL were collected. GFC was not performed on samples with serum cTnT concentrations Ͻ0.1 g/L (approximately equivalent to 0.2 g/L cTnI with the Centaur assay), because such samples would not give detectable cTn concentrations in the GFC fractions. We prepared control serum by diluting a partially purified extract of human cTn (Troponin complex -Extract grade; gift from SCIPAC Ltd, Sittingbourne, UK) 1 in 1600 with serum.
We assayed serum and column fractions for cTnT on an Elecsys 1010 analyzer using the Troponin T STAT method (Roche Diagnostics and cTnI using the Centaur ADVIA UltraTnI assay (Siemens Medical Solutions Diagnostics) and Access2 AccuTnI assay (Beckman Coulter). The Roche cTnT assay employs a capture antibody that recognizes amino acids 136 -147 and a detection antibody recognizing amino acids 125-131. The Siemens cTnI assay uses 3 anti-cTnI antibodies: 2 capture antibodies (recognizing amino acids 41-49 and 87-91) and 1 detection antibody (recognizing amino acids 27-40). The Beckman cTnI assay uses 2 anti-cTnI antibodies (amino acids 24 -40 and 41-49). For the endogenous molecular mass markers, we measured albumin on an Abbott Architect c8000 analyzer (Abbott Diagnostics) using the urine albumin assay, and prolactin on an Elecsys 1010 analyzer (Roche Diagnostics).
Results
The patterns of change of total serum cTnI and cTnT over time after AMI for each patient were similar, with a peak at 12 or 24 h after the onset of chest pain (Table  2 ). In 5 admission samples the troponin concentration or sample volume was too low for chromatographic analysis.
An illustrative chromatogram (patient B) can be seen in Fig. 1 . Three hours after onset of chest pain (B1), the detectable cTnI elutes in a position consistent with binary complex, and the lack of detectable cTnT in the same fractions eliminates the possibility of a ternary TIC complex. At the same time, cTnT elutes slightly earlier than prolactin (23 kDa) in a position consistent with the presence of free cTnT (37 kDa). At 12 (B2) and 24 (B3) h after onset of chest pain, the left-hand cTnT peak is thought to represent the ternary TIC complex (77 kDa), distinguished by the presence of both cTnI and cTnT immunoreactivity with the cTnT peak eluting slightly earlier than albumin (67 kDa). TIC forms the leading edge (in some other patient samples it forms a shoulder) of the peak of cTnI immunoreactivity and represents unresolved TIC and binary IC complex. The IC component of the peak elutes slightly later than albumin. The right-hand cTnT peak is again free cTnT (37 kDa). The percentage of total cTnT present within the peak corresponding to TIC was 17.2% (B2) and 32.3% (B3). In the final sample from this patient, taken 51 h after onset of chest pain, the pattern resembles that seen in the first sample, with only the IC complex and free cTnT present. The same pattern described above was seen in the 2 patients (A and D) who did not receive thrombolysis. The chromatograms for the remaining 9 patients can be found in the Data Supple- ment that accompanies the online version of this article at http://www.clinchem.org/content/vol56/issue6. In all 10 patients, at all time points, the predominant peak of cTnT immunoreactivity was in the molecular mass range corresponding to free cTnT. Four of the 10 patients (patients A, B, D, and L) showed the presence of cTnT and cTnI immunoreactivity in the fractions corresponding to the molecular mass of TIC complex. The percentage of total cTnT present within the peak corresponding to TIC in these cases was 17.5% (A2), 9.1% (A3), 17.2% (B2), 32.3% (B3), 10.4% (D4), and 5.9% (L3). TIC was thus a minor component of the total cTnT immunoreactivity in each case and was detected at different time points but not in any of the samples taken on admission. For patient samples in which sufficient troponin was present to allow chromatography of the admission sample (patients A, B, D, F, and M), cTnT was present only in the free form.
The majority of cTnI in all samples at all time points eluted just after albumin, suggesting that this predominantly represented the binary IC complex (approximately 42 kDa). We expected free cTnI to elute with prolactin but could detect little immunoreactive cTnI in these GFC fractions. No free low molecular mass cTnI forms were detected in any of the patients at any time. Traces of cTnI immunoreactivity were present in admission samples in patients B, D, F, and M; in all cases eluting in a position consistent with the IC complex.
An example of the cTnI pattern seen with the 2 cTnI assays can be seen in the online Data Supplement. In these chromatograms (except A1) there is a shoulder on the left-hand side of the cTnI peak that can be seen with both the Access and the Centaur assay, reflecting the presence of TIC. Although the Access results are quantitatively lower than those obtained with the Centaur assay, the cTnI peak shape in each chromatogram for each patient was very similar for both cTnI assays, indicating that both assays recognize the same forms of cTnI. The 12-h time points from each of the remaining patients are shown in the online Data Supplement.
We calculated the median recoveries for all patient sera examined, plus 8 SCIPAC samples run as internal QCs. To summarize, median (range) cTn recoveries for patient samples alone (n ϭ 35) were 86% (41%-110%) for cTnT, 49% (23%-134%) for cTnI Siemens Centaur, and 48% (23%-102%) for cTnI Beckman Access. Median cTn recovery for the SCIPAC samples (n ϭ 8) were 97% (70%-114%) for cTnT and 42% (35%-73%) for cTnI Siemens Centaur.
Discussion
The predominant forms of cTnI and cTnT after AMI are the binary IC complex and free (unbound) cTnT respectively, as reported by others (2, 3, 7, 9 ) . TIC was detected in 4 of 10 patients examined as a minor component of total cTnI consistent with other studies (2, 6, 9 ) . It is unclear why TIC was present in some patients' samples and not in others. Giuliani et al. (2 ) suggested that the presence of TIC may be indicative of a poor prognosis. Jaffe and Van Eyk (13 ) suggested that the presence of TIC may reflect later release of troponin from the structural pool in myocardial cells affected by ischemia, after the earlier release of free troponin subunits from the cytoplasmic pool. Our data would be consistent with this in that in the 5 patients in whom sufficient troponin was present to allow chromatogra- Black arrowheads indicate position of albumin and prolactin peaks. cTnI was measured by using the Siemens Centaur assay.
phy of the admission sample, cTnT was present in the free form only. Many previous studies of cTn forms after AMI have used SDS-PAGE, which uses harsh reducing conditions that dissociate troponin complexes. This denaturing could also impact on cTn recognition by anti-cTn antibodies. Furthermore, SDS-PAGE with Western blotting is not quantitative, and all reported studies have used antibodies different from those used in commercial clinical cTn assays. Consequently with the use of these approaches it is not possible to judge the prevalence of the different forms of troponin detected or their reactivity with clinical assays.
GFC requires minimal sample manipulation, allowing direct demonstration of the presence of complexes and the study of cTn forms detected by clinical assays. It also allows an assessment of the relative contribution of the different forms of troponin to the total serum immunoreactivity and allows estimation of immunoreactive troponin recovery after chromatography. In this respect the recovery of cTnI (49%) was disappointing. Possible explanations for this low recovery include changes in the tertiary structure or protein-protein interactions that alter antibody recognition or proteolytic degradation. Other investigators have commented on the lability of cTnI (14 ) , whereas cTnT appears robust. For previous GFC studies recovery data for the analytes under investigation have not been reported. We estimated recovery of cTnI from the data of Wu et al. (9 ) as 53% for patient 1 and 25% for patient 2 (data for patient 3 were not shown).
Some of the samples without TIC (as judged by the absence of cTnT immunoreactivity in the first eluting peak) contained a shoulder on the leading edge of the IC peak, which provides possible evidence of the presence of high molecular mass forms of cTnI as previously observed (5 ) . We found no evidence of truncated forms of free cTnI, although the resolution of GFC may be insufficient to demonstrate the presence of IC complexes of differing molecular mass due to N-or C-terminal truncation of the cTnI component.
Knowledge of the degradation pattern of cTnI has prompted clinical assay manufacturers to design anticTnI antibodies directed against the stable central cTnI domain. These antibodies should reduce the impact of one source of the difference in results obtained by different assays. The Centaur and Access assays both employ antibodies directed at the central region of cTnI, and the results presented here suggest that the assays react similarly with the different forms of cTnI separated by GFC. The considerable differences observed in absolute cTnI concentrations obtained with the 2 assays are probably due to standardization differences.
After AMI, we found that circulating cTnT appeared to be present predominantly in the free, intact form. This observation conflicts markedly with the findings of other investigators using SDS-PAGE (5, 6, 8 ) , who demonstrated the presence of truncated forms of cTnT. It is particularly noteworthy that Michielsen et al. (8 ) observed no intact cTnT in the circulation more than 12 h after the cTnT concentration started to increase above the AMI cutoff. Labugger et al. (5, 6 ) used an anti-cTnT antibody directed against the amino acid 3-15 epitope, whereas the antibodies used in the Roche assay reacted with amino acids 125-131. It is possible therefore that the conflicting results of these studies are due to different antibody specificity. Michielsen et al. (8 ) used anti-cTnT antibody 4C5 (BiosPacific/Fortron) in one of their studies but did not provide data on antibody epitopes. In a further study of cTnT, however, Michielsen et al. (15 ) obtained conflicting results when they compared GFC with the Roche cTnT assay and SDS-PAGE and Western blotting with an anti-cTnT antibody that recognized amino acids 1-60.
The identification of cTn species present at varying time points after AMI in patient sera should aid in the design of future cTn assays with optimum clinical sensitivity. The data obtained from the present study show that the Centaur and Access cTnI assays react largely with IC and with TIC when this is present. We found no evidence of free cTnI or truncated forms of free cTnI, perhaps because such forms of cTnI are present in relatively low concentrations or are poorly detected by the antibodies in the Access and Centaur assays. Our findings with the Roche cTnT assay can be interpreted in a similar fashion. We found that this assay reacts largely with free, intact cTnT and with TIC when this is present. We found no evidence that the Roche assay was reacting with lower molecular mass forms of cTnT, but again this may be because such forms were present in relatively low concentrations or because the Roche antibodies reacted weakly with them.
Knowledge of the cTn forms present in AMI patient serum that are detected by clinical assays should also facilitate the choice of standards, QC, and external quality assessment materials for cTn assays. It has been claimed that the proposed cTnI calibrator SRM 2921 is mostly (85%) TIC complex with some (15%) IC complex present (16 ) . Our data suggest that use of a material that contains predominantly TIC complex as a standard may not be ideal because TIC complex is not seen in every AMI patient and is not the predominant form of cTnI. It is noteworthy that a trial of SRM 2921 showed that the proportion of cTnI methods that demonstrated commutability was too low to recommend the use of SRM 2921 as a common calibrator (17 ) . Differences between the nature of the troponin complexes in the SRM compound and the circulating com-plexes were proposed as an explanation for this poor commutability (17 ) , although differences in the antibody strategies used in commercial assays may also be contributory.
